You need to register to watch content!

Course Information

Course Instructor

Author
 

MPN-MDS EU Focus Meeting

€1,000.00

Registration fee

Complimentary coupon code for supporters can be added at checkout.

 
Continue

Opening Introduction to the meeting

Ryan Fitzpatrick, CEO, MD Education

Session I: Mutations and Classification of MPN and MDS

CHIP and MPN, Steffen Koschmieder, RWTH Aachen University, Germany
CHIP and MDS, Liran Shlush, Weizmann Institute of Science, Israel
ICC vs WHO for MPN, Alessandro M. Vannucchi, University of Florence, Italy
ICC vs WHO for MDS, Maria Teresa Voso, UOSD Diagnostica Avanzata Oncoematologica del Policlinico di Tor Vergata (PTV), Italy
Session I: Mutations and Classification of MPN and MDS Panel Discussion

Session II: Polycythemia vera (PV)

Debate I: Standard of care for low-risk PV: Phlebotomy, Mary Frances McMullin, Queen’s University Belfast, Ireland
Standard of care for low-risk PV: Interferon, Tiziano Barbui, University of Bergamo, Italy
Session II: Polycythemia vera (PV) Debate 1
Debate II: Standard of care for high-risk PV: Interferon, Heinz Gisslinger, Medical University of Vienna, Austria
Standard of care for high-risk PV: Hydroxyurea/ruxolitinib, Rajko Kušec, University hospital Dubrava Zagreb, Croatia
Session II: Polycythemia vera (PV) Debate 2

Session III: Essential Thrombocytopenia (ET) and special situations

What is “high-risk” ET? Current and future therapies, Paola Guglielmelli, University of Florence, Italy
Pregnancy in MPN: State of the art management, Martin Griesshammer, Ruhr-Universität Bochum, Germany
MPN and SVT: Diagnosis and management,Jean-Jacques Kiladjian, Université Paris Cité, France
Session III: Essential Thrombocytopenia (ET) and special situations Panel Discussion

Session IV: Myelofibrosis (MF)

Management of early/prefibrotic MF: Does early intervention matter?, Lucia Masarova , MD Anderson Cancer Center, USA
Cytopenic MF: emerging area for novel approaches, Paola Guglielmelli, Univerisity of Florence, Italy
First line therapy for Int2/High risk MF: where is the field going?, Alessandro Vannucchi, University of Florence, Italy
Session IV: Myelofibrosis (MF) Panel Discussion

Session V: Other MPNs and Overlap Syndromes

Aggressive systemic mastocytosis: emerging therapeutic options, Deepti Radia, Guy’s and St. Thomas’ NHS Foundation Trust, UK
Eosinophilic neoplasms: emerging therapeutic options, Andreas Reiter, University Medical Centre Mannheim, Germany
Myeloproliferative Neoplasm-Unclassifiable (MPN-U), Donal P McLornan, University College London Hospitals NHS Trust, UK
CML the paradigm for MPN, Elias Jabbour, MD Anderson Cancer Center, USA
Session V: Other MPNs and Overlap Syndromes Panel Discussion

Session VI: Other MPNs and Overlap Syndromes (cont.)

Clinical trials in MDS/MPN: How Can we stand alone, Michael Savona, Vanderbilt University, Nashville, USA
Diagnosis and management of MDS/MPN-U, Andrew Kuykendall, Moffitt Cancer Center, Florida, USA
An update on CMML, Eric Solary, Université Paris-Saclay, France
Session VI: Other MPNs and Overlap Syndromes Panel Discussion

Session VII: Hematopoietic stem cell transplantation (HSCT)

Debate: HSCT for MF: Earlier?, Ruben Mesa, Wake Forest University in Winston-Salem, USA
Debate: HSCT for MF: Later?, Ibrahim Yakoub-Agha, Lille University Hospital, Lille, France
Session VII: Hematopoietic stem cell transplantation (HSCT) Panel discussion
Debate: HSCT for MDS: Earlier?, Matteo Della Porta, Humanitas University, Italy
Debate: HSCT for MDS: Later?, Valeria Santini, University of Florence, Italy
Management of iron overload in MDS: who, when?, Marlijn Hoeks, Radboud University Medical Centre (Radboudumc), Netherlands
Session VII: Hematopoietic stem cell transplantation (HSCT) Panel discussion 2

Session VIII: Myelodysplastic Syndromes (MDS)

Standard and new drugs in higher risk MDS, Thomas Clazeua, Centre Hospitalier Universitaire de Nice, France
Anemia in MDS and SF3B1 mutated MDS, Luca Malcovati, IRCCS S. Matteo Hospital Foundation & University of Pavia, Italy
Standard and New drugs in low-risk MDS, Rami Komrokji, MD Anderson Cancer Center, USA
The resistance to treatment especially hypomethylating agents, Lucia Messingerova, Slovak Academy of Sciences, Slovakia
Managing secondary AML: from MDS and MPN, Naval Daver, MD Anderson Cancer Center, USA
Session VIII: Myelodysplastic Syndromes (MDS) Panel discussion

MPN-MDS EU Focus Meeting 2023

It is our pleasure to invite you to participate in this one-of-a-kind event.

If you need additional information please contact us at: office@md-education.com

MD Education
4/4a Bloomsbury Square,
London, WC1A 2RP

MD Education USA LLC
4600 140th Avenue North Suite,
180 Clearwater, Florida 33762